HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Massachusetts Secretary of the Commonwealth William Galvin subpoena Gillette President & CEO James Kilts to testify June 1 regarding fairness opinions generated by Goldman, Sachs & Co. and UBS Securities in connection with the firm's acquisition by Procter & Gamble. Galvin also issues May 19 subpoenas al testificandum to Goldman Sachs employees Jack Levy and Stephan Feldgoise and UBS Securities' Richard Case and Blair Effron relating to fairness opinions provided by the firms. Galvin previously issued subpoenaes to Gillette employees in connection with the acquisition, which he has been investigating since February (1"The Rose Sheet" May 16, 2005, In Brief and 2"The Rose Sheet" Feb. 7, 2005, p. 8)...

You may also be interested in...


Massachusetts Secretary of the Commonwealth William Galvin issues subpoenas ad testificandum to several Gillette employees on May 11 to testify in connection with the state Securities Division's investigation of Procter & Gamble's acquisition of the razor manufacturer. Among those subpoenaed to testify later this month are Gillette CFO Charles Cramb, Board of Directors Vice Chairman Edward Degraan and Human Resources Manager Edward Guillet. Galvin has been investigating the merger since February, shortly after it was announced (1"The Rose Sheet" Feb. 7, 2005, p. 8). Gillette has resisted previous subpoenas issued by Galvin, recently requesting a Suffolk Superior Court quash a request for additional documents pertaining to the merger. The court ruled in favor of Gillette April 28 (2"The Rose Sheet" May 9, 2005, p. 7)...

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts